8 research outputs found

    Анализ модельного риска использования технологии мультипликаторов при оценке акций российских компаний

    Get PDF
    This work is a new direction in the authors’ previous study on applying the market multipliers in assessing the value of oil and gas companies. The work is based on the findings of statistical studies of multipliers calculated for the industry, as well as their volatility over a 12-year period — from 2006 to 2017 inclusively, as exemplified by 46 companies from nine sectors of the economy of the Russian Federation. The analysis of the risk measures Value-at-Risk (hereinafter VaR) and Expected Shortfall (hereinafter ES) was conducted by means of volatility calculated in different ways. In particular, the multiplier volatility was introduced by V. B. Minasyan. It was established that for all nine sectors of the Russian economy, calculated with conventional stock volatility statistics (when possible), risk valuation measures VaR and ES led to lower calculated risk values compared to those calculated using multiplier volatility. The results of the study are of interest to evaluators, investors and other interested parties, as it allows to analyze the general behavior of the stock value in Russian companies and to compare the change in indicators of various economic sectors in terms of multiplier technology.Данная работа является новым направлением развития ранее проведенного авторами исследования проблемы, связанной с применением метода рыночных мультипликаторов в оценке ценности компаний нефтегазовой отрасли. Работа основана на выводах статистических исследований мультипликаторов, рассчитанных для отрасли, а также их волатильности за 12-летний период — с 2006 по 2017 г. включительно на примере 46 компаний из девяти отраслей экономики Российской Федерации. Проведен анализ мер риска Value-at-Risk (далее — VaR) и Expected Shortfall (далее — ES), вычисленных с волатильностью, рассчитанной разными способами. В частности, использовалась мультипликаторная волатильность, введенная в обиход В. Б. Минасяном. Установлено, что по всем девяти отраслям экономики РФ оценки мер риска VaR и ES, рассчитанные с помощью обычных статистических данных волатильности акции (когда это возможно), приводили к меньшим расчетным величинам риска по сравнению с теми, что рассчитаны с применением мультипликаторной волатильности. Результаты исследования представляют интерес для оценщиков, инвесторов и других заинтересованных лиц, так как позволяют проанализировать общую картину поведения стоимости акций российских компаний и дают возможность сравнить изменение показателей различных отраслей экономики в рамках использования технологии мультипликаторов

    Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

    Get PDF
    IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

    Model Risk Analysis of Multiplier Technology Applied at Stock Valuation of Russian Companies

    Get PDF
    This work is a new direction in the authors’ previous study on applying the market multipliers in assessing the value of oil and gas companies. The work is based on the findings of statistical studies of multipliers calculated for the industry, as well as their volatility over a 12-year period — from 2006 to 2017 inclusively, as exemplified by 46 companies from nine sectors of the economy of the Russian Federation. The analysis of the risk measures Value-at-Risk (hereinafter VaR) and Expected Shortfall (hereinafter ES) was conducted by means of volatility calculated in different ways. In particular, the multiplier volatility was introduced by V. B. Minasyan. It was established that for all nine sectors of the Russian economy, calculated with conventional stock volatility statistics (when possible), risk valuation measures VaR and ES led to lower calculated risk values compared to those calculated using multiplier volatility. The results of the study are of interest to evaluators, investors and other interested parties, as it allows to analyze the general behavior of the stock value in Russian companies and to compare the change in indicators of various economic sectors in terms of multiplier technology

    PRIMARY AND SECONDARY GLOMERULONEPHRITIDES 1

    No full text
    corecore